Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Kopin Corp's Q4 Revenue Drops 42%

Kopin Corp. said fourth-quarter revenue fell 42% from a year earlier as a government shutdown delayed procurement and shipments, even as the company raised $56 million from strategic and institutional investors and expanded defense partnerships.

Total revenue in the quarter ended Dec. 27, 2025, dropped to $8.4 million from $14.6 million in the same period a year earlier. Product revenue fell 56% to $5.6 million from $12.6 million. Non-product revenue rose 47% to $2.5 million from $1.7 million.

Costs moved differently: cost of product revenues declined to $4.7 million from $10.6 million, while research and development spending increased 13% to $3.5 million from $3.1 million. Selling, general and administrative expenses rose 45% to $4.5 million from $3.1 million, reflecting higher professional fees and outside service costs tied to the capital raise and partnership transactions.

Cash and cash equivalents totaled $37.8 million at quarter-end. Kopin also reported $23.0 million of bonded cash as a long-term asset. The company said its overall cash position improved after the $56 million private placement.

Operationally, Kopin said sales began under its strategic partnership with Theon International, with a three-year plan targeting revenue and technology sharing across Europe, Southeast Asia and NATO markets. It also said progress continued on color microLED development for soldier-borne mission systems, with several prime contractor selections and technology acquisition wins expected.

The company said product order flow has returned to anticipated levels, while new European product orders have exceeded forecast. As a result of these announcements, the company's shares have moved 11.49% on the market, and are now trading at a price of $3.30. For the full picture, make sure to review KOPIN CORP's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS